Investigators have proposed a new approach to prostate cancer (PCa) screening in which a PSA level of 1.5 ng/mL or higher should prompt primary care physicians—who order most PSA screening tests—to consider referring patients to a urologist for further evaluation. Men who have a PSA below 1.5 ng/mL would have a routine follow-up PSA test in 5 years.
“In our algorithm, we recommend that a biopsy should not be performed unless the risk of an aggressive tumor is significant, and following a thorough discussion of benefits and risks with the patient,” the investigators, led by E. David Crawford, MD, of the University of Colorado, Denver, wrote in Urology (2016;96:116-120). “These discussions should emphasize that the purpose of screening is the early identification of potentially lethal disease, and that in most cases low-risk tumors, if identified, do not require immediate treatment.”
Under their proposed new approach, primary care physicians (PCPs) would refer to urologists those patients who have a PSA level of 1.5 ng/mL or higher or abnormal digital rectal examination (DRE) results. Urologists then would explore possible causes for elevated PSA or abnormal DRE results, including PCa, benign prostatic hyperplasia, and prostatitis. For patients suspected of having PCa, urologists would consider ordering genomic tests such as the Prostate Health Index, 4Kscore, or SelectMDx assays. Patients deemed to be at high risk for aggressive cancer would be considered for transrectal ultrasound-guided prostate biopsy. Patients at low risk for aggressive cancer would be referred to their PCPs for repeat PSA testing in 1 year.
This algorithm is similar to that used for an elevated blood sugar, where an abnormal result triggers another test, such as an A1C hemoglobin test, the investigators stated.
PCPs, who order approximately 90% of PSA screening tests, are confused about the messages they receive regarding PSA, Dr Crawford's group stated. “We believe that a simple message using a PSA cutoff of 1.5 ng/mL is reflective of what PCPs often experience with conditions such as mild hypertension and prediabetes,” they wrote. “In this paper, we have presented an alternative approach in which screening is performed for men with at least a 10-year life expectancy.”
Previous research has shown that men with a PSA level of 1.5 ng/mL or higher at a younger age are at increased risk for the development of any PCa and significant PCa later in life. Dr Crawford's group cited a study by Hans Lilja, MD, and colleagues published in Cancer(2011;117:1210-1219) showing that approximately 5% of men who had a PSA value of 1.5 ng/mL or higher when blood was drawn at ages 44 to 50 years will be found to have advanced PCa 20 to 25 years later.
The investigators also reported data from BioReference Laboratories, Inc., showing that approximately 30% of men aged 45 to 70 years have a PSA level of 1.5 ng/mL or above.
Patients with metastatic or high-risk prostate cancer (PCa) treated with degarelix have improved PSA progression-free survival compared with those treated with luteinizing hormone-releasing hormone (LHRH) antagonists, investigators reported at the European Society for Medical Oncology 2016 congress in Copenhagen.
The finding is from a pooled analysis of data from patients in the Americas, Europe, and Asia. Neal Shore, MD, of Carolina Urologic Research Center in Myrtle Beach, South Carolina, and collaborators pooled data from 2 pivotal phase 3 randomized trials of men with PCa where androgen-deprivation therapy (ADT) was indicated for men with metastatic disease or those with PSA relapse deemed at high risk of progression. The investigators defined PSA progression-free survival (PSA-PFS) as death from any cause or PSA recurrence (2 consecutive increases of at least 50% 2 or more weeks apart and at least a 5 ng/mL increase from nadir.
The investigators defined high-risk PCa as baseline PSA level greater than 20 ng/mL or Gleason score 8–10; they defined metastatic PCa by baseline TNM staging.
The study population included 60 patients from the Americas, 97 from Europe, and 224 from China. The patients were randomly assigned 193 patients to receive the gonadotropin-releasing hormone (GnRH) degarelix and 188 to receive an LHRH agonist (leuprolide or goserelin).
Patients who received degarelix had significantly improved PSA-PFS compared with those treated with an LHRH agonist, regardless of geographic region. Compared with European patients, however, Chinese and American patients had a significant 52% and 74% decreased risk for PSA-PFS, respectively, Dr Shore's group reported.
“These results suggest delay of disease progression with initial use of a GnRH antagonist as compared with LHRH agonists across global regions,” the investigators concluded in their study abstract.
Με το ιστολόγιο αυτό επιχειρείται η κατά το δυνατόν άμεση ενημέρωση σε θέματα που αφορούν ουρολογικές εξελίξεις και δίνεται η δυνατότητα σχολιασμού των αναρτήσεων.
Ιατρείο Θεσσαλονίκης: Εθνικής Αντιστάσεως 74, Καλαμαριά
Τ: 2310 44 44 62, Κ: 693 63 23 794
Ιατρείο Λαγκαδά: Δ. Μήλιου 24 (έναντι 1ου δημοτικού), Λαγκαδάς
Τ: 2394 020 780, Κ: 693 63 23 794